Sermorelin Peptides

EVIDENCE DASHBOARD · 20 PRIMARY SOURCES

References: sermorelin Research Literature

All citations used across this sermorelin evidence-intelligence dashboard. Each entry includes authors, journal, year, DOI or PMID where available, and a direct URL to the primary source.

  1. [1]
    Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology and Metabolism. 1996;81(3). View source ↗
    DOI: 10.1210/jcem.81.3.8772599 · PMID: 8772599
  2. [2]
    Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2). View source ↗
    DOI: 10.2165/00063030-199912020-00007 · PMID: 18031173
  3. [3]
    Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American Journal of Men's Health. 2017. View source ↗
    DOI: 10.1177/1557988317718662 · PMID: 28830317
  4. [4]
    EMD Serono. Sermorelin Acetate (Geref) Prescribing Information. FDA-approved prescribing information. 2008. View source ↗
  5. [5]
    Jessup SK, Malow BA, Symons KV, Barkan AL. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. European Journal of Endocrinology. 2004;151(5). View source ↗
    DOI: 10.1530/eje.0.1510561 · PMID: 15538933
  6. [6]
    Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. Journal of Pediatrics. 1996;128(5 Pt 2). View source ↗
    DOI: 10.1016/s0022-3476(96)70008-2 · PMID: 8627466
  7. [7]
    Schier T, Guldner J, Colla M, Holsboer F, Steiger A. Changes in sleep-endocrine activity after growth hormone-releasing hormone depend on time of administration. Journal of Neuroendocrinology. 1997;9(6). View source ↗
    DOI: 10.1046/j.1365-2826.1997.00565.x · PMID: 9089471
  8. [8]
    Born J, Muth S, Fehm HL. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology. 1988;13(3). View source ↗
    DOI: 10.1016/0306-4530(88)90021-2 · PMID: 3406323
  9. [9]
    Goldenberg N, Horowitz JF, Gorgey A, Sakharova A, Barkan AL. Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans. Clinical Diabetes and Endocrinology. 2022. View source ↗
    DOI: 10.1186/s40842-022-00137-y · PMID: 35101148
  10. [10]
    Pontiroli AE, Lanzi R, Monti LD, Sandoli E, Pozza G. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. Journal of Clinical Endocrinology and Metabolism. 1991;72(2). View source ↗
    DOI: 10.1210/jcem-72-2-492 · PMID: 1671389
  11. [11]
    Smith RG, Thorner MO. Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2023. View source ↗
    DOI: 10.1093/gerona/glad022 · PMID: 37325967
  12. [12]
    Fernandez-Garza LE, Guillen-Silva F, Sotelo-Ibarra MA, Dominguez-Mendoza AE, Barrera-Barrera SA, Barrera-Saldana HA. Growth hormone and aging: a clinical review. Frontiers in Aging. 2025. View source ↗
    DOI: 10.3389/fragi.2025.1549453
  13. [13]
    Multiple authors (meta-analysis). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Reviews. 2025. View source ↗
    DOI: PMID 41545261 · PMID: 41545261
  14. [14]
    Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C. Modulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults. Mechanisms of Ageing and Development. 2008. View source ↗
    DOI: 10.1016/j.mad.2008.08.001 · PMID: 18762207
  15. [15]
    EMD Serono. Sermorelin Acetate (Geref) Prescribing Information — Clinical Trials Adverse Events. FDA-approved prescribing information. 2008. View source ↗
  16. [16]
    Smith RG, Thorner MO. Growth Hormone Secretagogues as Potential Therapeutic Agents to Restore Growth Hormone Secretion in Older Subjects to Those Observed in Young Adults (capromorelin multicenter data). Journals of Gerontology Series A. 2023. View source ↗
    DOI: 10.1093/gerona/glad022 · PMID: 37325967
  17. [17]
    Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Annals of Internal Medicine. 2008;149(9). View source ↗
    DOI: 10.7326/0003-4819-149-9-200811040-00010 · PMID: 18981489
  18. [18]
    Sinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020. View source ↗
  19. [19]
    Wikipedia contributors. Sermorelin — structural and pharmacokinetic data. Wikipedia. 2024. View source ↗
  20. [20]
    FDA / Federal Register. Determination That GEREF (Sermorelin Acetate) Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register. 2013. View source ↗